Alzheimer's disease is a neurodegenerative disease that greatly affects the quality of life of patients and their caregivers and places a heavy cost burden on the healthcare system. The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine have a central role in the treatment of Alzheimer's disease in the mild to moderate stages. Clinical trials with ChEIs have demonstrated therapeutic benefits for symptoms of cognition, function and behaviour across the disease course. These agents are most effective when started early in the disease course and used persistently, without treatment gaps. Early recognition of Alzheimer's disease and a global evaluation of treatment effectiveness are therefore essential. This article identifies barriers to early recognition and effective care of patients with Alzheimer's disease and discusses practical strategies to overcome them.
WatkinsPBZimmermanHJKnappMJGraconSILewisKW: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA1994; 271: 992–998.
2.
BurnsARossorMHeckerJGauthierSPetitHMollerHJ: The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord1999; 10: 237–244.
3.
Corey-BloomJAnandRVeach J, for the ENA 713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol1998; 1: 55–65.
4.
RaskindMAPeskindERWesselTYuanW: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology2000; 54: 2261–2268.
5.
RogersSLFriedhoffLT: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, doubleblind, placebo-controlled trial. The Donepezil Study Group. Dementia1996; 7: 293–303.
6.
RogersSLDoodyRSMohsRCFriedhoffLT: Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med1998; 158: 1021–1031.
7.
RogersSLFarlowMRDoodyRSMohsRFriedhoffLT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology1998; 50: 136–145.
8.
RoslerMAnandRCicin-SainAGauthierSAgidYDal-BiancoP: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ1999; 318: 633–638. [Published erratum appears in: BMJ 2001; 322: 1456].
9.
TariotPNSolomonPRMorrisJCKershawPLilienfeldSDingC: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology2000; 54: 2269–2276.
10.
WilcockGKLilienfeldSGaensE: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ2000; 321: 1445–1449. [Published erratum appears in BMJ 2001; 322: 405].
11.
PotkiSGAnandRHartmanRVeachJGrossbergG: Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry2002; 26: 713–720.
12.
DoodyRSGeldmacherDSGordonBPerdomoCAPrattRD;Donepezil Study Group: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol2001; 58: 427–433.
13.
FarlowMAnandRMessinaJJrHartmanRVeachJ: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol2000; 44: 236–241.
14.
WinbladBEngedalKSoininenHWaldemarGVerheyFWimoA: Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a 1-year placebo-controlled study and two-year follow-up study [abstract]. Int Psychogeriatr2003; 15 (Suppl. 2): 293–294.
15.
RaskindMTruyenLKershawP: Long-term safety and tolerability of galantamine in Alzheimer's disease: An open-label extension with up to 54 months' exposure. In: Proceedings of the 16th Annual Meeting of the American Association for Geriatric Psychiatry. Bethesda: American Association of Geriatric Psychiatry2003; pp 90–91.
16.
SeltzerBZolnouniPNunezMKumarDGoldmanRIeniJ: Donepezil treatment benefits in early-stage Alzheimer's disease. J Am Geriatr Soc2003; 51: S100–S101.
17.
BartusRTDeanRL3rdBeerBLippaAS: The cholinergic hypothesis of geriatric memory dysfunction. Science1982; 217: 408–417.
18.
DrachmanDALeavittJ. Human memory and the cholinergic system: A relationship to aging?Arch Neurol1974; 30: 113–121.
19.
DavisKLMohsRCMarinDPurohitDPPerlDPLantzM: Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA1999; 21: 1401–1406.
20.
DeKoskySTIkononomovicMDStyrenSDBeckettIWisniewskiSBennettDA: Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol2002; 51: 145–155.
21.
KrishnanKRCharlesHCDoraiswamyPMMintzerJWeislerRYuX: Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry2003; 160: 2003–2011.
22.
JessenFBlockWTraberFKellerEFlackeSLamerichsR: Decrease of N-acetylas-partate in the MTL correlates with cognitive decline of AD patients. Neurology2001; 57: 930–932.
23.
StaffRTGemmellHGShanksMFMurrayADVenneriA: Changes in the rCBF images of patients with Alzheimer's disease receiving donepezil therapy. Nucl Med Commun2000; 21: 37–41.
24.
TuneLTiseoPJIeniJPerdomoCPrattRDVotawJR: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: Results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry2003; 11: 169–177.
25.
StefanovaEBlennowKAlmkvistOHellstrom-LindahlENordbergA: Cerebral glucose metabolism, cerebrospinal fluid-β-amyloid1-42 (CSF-Aβ42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett2003; 338: 159–163.
26.
AkasofuSKosasaTKimuraMKubotaA: Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol2003; 472: 57–63.
27.
ZhouJFuYTangXC: Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett2001; 306: 53–56.
28.
TakadaYYonezawaAKumeTKatsukiHKanekoSSugimotoH: Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther2003; 306: 772–777.
29.
WangX-DChenX-QYangH-HHuG-Y: Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex. Neurosci Lett1999; 272: 21–24.
30.
WinbladBEngedalKSoininenHVerheyFWaldemarGWimoA: Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology2001; 57: 489–495.
31.
RogersSLDoodyRSPrattRDIeniJR: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol2000; 10: 195–203.
32.
RaskindMAPeskindERTruyenLKershawPDamarajuCV: The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial. Arch Neurol2004; 61: 252–256.
33.
MohsRCDoodyRSMorrisJCIeniJRRogersSLPerdomoCAPrattRD;“312” Study Group: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology2001; 57: 481–488. [Published erratum appears in Neurology 2001; 57: 1942].
34.
HughesCPBergLDanzigerLWCobenLAMartinRL: A new clinical scale for the staging of dementia. Br J Psychiatry1982; 140: 566–572.
35.
CallahanCMHendrieHCTierneyWM: Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med1995; 122: 422–429.
36.
GeldmacherDS: Cost-effective recognition and diagnosis of dementia. Semin Neurol2002; 22: 63–70.
37.
BoiseLCamicioliRMorganDLRoseJHCongletonL: Diagnosing dementia: Perspectives of primary care physicians. Gerontologist1999; 39: 457–464.
38.
JohannsenPBarcikowskaMHeunRHolubRJakobsenSTriauE: Donepezil treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: Results from a randomized placebo-controlled trial. J Neurol2003; 250 (Suppl. 2): II/126.
39.
GeldmacherDSProvenzanoGMcRaeTMasteyVIeniJR: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc2003; 51: 937–944.
40.
LopezOLBeckerJTWisniewskiSSaxtonJKauferDIDeKoskyST: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry2002; 72: 310–314.
41.
CummingsJLSchneiderLTariotPNKershawPRYuanW: Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry2004; 161: 532–538.
42.
FeldmanHGauthierSHeckerJVellasBEmirBMasteyV: Donepezil MSAD Study Investigators Group: Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc2003; 51: 737–744.
43.
MasteyVWinbladBWimoAHaglundAJacobsonLMiceliR: Donepezil reduces the time caregivers spend providing care: Results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer's disease. Am J Geriatr Psychiatry2001; 49: S20.
44.
Migliaccio-WalleKGetsiosDCaroJJIshakKJO'BrienJAPapadopoulosGAHEAD Study Group: Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther2003; 25: 1806–1825.
45.
CourtneyCFarrellDGrayRHillsRLynchLSellwoodE: AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet2004; 363: 2105–2115.
